Evidence map›Paper›PMID 36255622›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Analysis of HDACi-Coupled Nanoparticles: Opportunities and Challenges.

Marie Kühne, Susanne Hofmann, Henry Lindemann, Zoltán Cseresnyés, Andreas Dzierza, Daniel Schröder, Maren Godmann, Andreas Koschella, Christian Eggeling, Dagmar Fischer and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marie KühneInstitute of Biochemistry and Biophysics, Center for Molecular Biomedicine, Friedrich Schiller University Jena, Jena, Germany.
Susanne HofmannInstitute of Biochemistry and Biophysics, Center for Molecular Biomedicine, Friedrich Schiller University Jena, Jena, Germany.
Henry LindemannInstitute for Organic Chemistry and Macromolecular Chemistry, Center of Excellence for Polysaccharide Research, Friedrich Schiller University Jena, Jena, Germany.
Zoltán CseresnyésApplied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Friedrich Schiller University Jena, Jena, Germany.
Andreas DzierzaDivision of Pharmaceutical Technology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Daniel SchröderInstitute of Applied Optics and Biophysics, Friedrich Schiller University Jena, Jena, Germany.
Maren GodmannInstitute of Biochemistry and Biophysics, Center for Molecular Biomedicine, Friedrich Schiller University Jena, Jena, Germany.
Andreas KoschellaInstitute for Organic Chemistry and Macromolecular Chemistry, Center of Excellence for Polysaccharide Research, Friedrich Schiller University Jena, Jena, Germany.
Christian EggelingInstitute of Applied Optics and Biophysics, Friedrich Schiller University Jena, Jena, Germany.
Dagmar FischerDivision of Pharmaceutical Technology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Marc Thilo FiggeApplied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Friedrich Schiller University Jena, Jena, Germany.
Thomas HeinzeInstitute for Organic Chemistry and Macromolecular Chemistry, Center of Excellence for Polysaccharide Research, Friedrich Schiller University Jena, Jena, Germany.
Thorsten HeinzelInstitute of Biochemistry and Biophysics, Center for Molecular Biomedicine, Friedrich Schiller University Jena, Jena, Germany. T.Heinzel@uni-jena.de.

Funding

Medical Research Council MC_UU_00008/9Medical Research Council MC_UU_12010/9
6 · The paper itself

Abstract

Systemic administration of histone deacetylase inhibitors (HDACi), like valproic acid (VPA), is often associated with rapid drug metabolization and untargeted tissue distribution. This requires high-dose application that can lead to unintended side effects. Hence, drug carrier systems such as nanoparticles (NPs) are developed to circumvent these disadvantages by enhancing serum half-life as well as organ specificity.This chapter gives a summary of the biological characterization of HDACi-coupled NPs in vitro, including investigation of cellular uptake, biocompatibility, as well as intracellular drug release and activity. Suitable methods, opportunities, and challenges will be discussed to provide general guidelines for the analysis of HDACi drug carrier systems with a special focus on recently developed cellulose-based VPA-coupled NPs.

Indexed as

Histone Deacetylase InhibitorsNanoparticlesCelluloseDrug CarriersValproic AcidCelluloseDrug CarriersHistone Deacetylase InhibitorsValproic AcidBiocompatibilityCellular uptakeCelluloseDrug delivery systemHemocompatibilityHistone deacetylase inhibitorImagingNanoparticleShell-less hen’s egg modelValproic acid

Identifiers

PMID36255622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.